Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to…
AutomateNexus Voice Launches AI-Powered Virtual Receptionist to Help Small Businesses Capture Every Lead
Celestion Brings Cutting-Edge Music Technology to Transform Hong Kong’s Modern Listening Experience
The FUTR Corporation Appoints Technology Financier G. Scott Paterson to its Board of Directors and as Chairman of the Board